Fresenius Adjusts Outlook: EBIT Forecast in Focus

EBIT Forecast Adjusted

After the preliminary figures for the first nine months of 2022 were released, Fresenius SE & Co. KGaA adjusted its earnings forecast for the current year. The DAX group now expects consolidated sales of around EUR 39.3 to 39.8 billion (previously: EUR 39.0 to 40.0 billion).

Earnings before interest and taxes (EBIT) are expected to be between EUR 4.6 and 4.8 billion (previously: EUR 4.7 to 5.0 billion).

The forecast for net income was also adjusted. Fresenius now expects a figure of EUR 2.6 to 2.8 billion (previously: EUR 2.7 to 3.0 billion).

Reasons for the Adjustment

The main reason for the adjustment is the continued difficult environment in the healthcare sector. In addition, the company cited the ongoing COVID-19 pandemic, rising inflation, and supply chain disruptions as challenges.

Fresenius also referred to the sale of its stake in Fresenius Helios, which was completed in August 2022. This had a negative impact on sales and earnings.

Outlook for 2023

For the coming year, Fresenius remains cautiously optimistic. The company expects consolidated sales growth of 4 to 6 percent. EBIT is expected to increase by 3 to 7 percent.

Fresenius CEO Michael Sen said: "We are facing major challenges, but we are convinced that we will emerge from this phase stronger. We are focusing on our core businesses and consistently implementing our strategy."